Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

Healthy Subjects Clinical Trial

Official title:

A Phase 1, 2-Part, Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Three Subcutaneous Injection Formulations of Ustekinumab in Healthy Male Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04428814
• Other study ID #: CT-P43 1.1
• Status: Completed
• Phase: Phase 1
• Start date: August 3, 2020
• Est. completion date: February 24, 2021

Study information

• Verified date: August 2021
• Source: Celltrion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase 1, 2-Part, Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Three Subcutaneous Injection Formulations of Ustekinumab (CT-P43, EU approved Stelara, and US licensed Stelara) in Healthy Male Subjects.

Description:

CT-P43 is being developed as a proposed biosimilar of Stelara (ustekinumab). This study will be conducted in 2 parts. In Part 1, subjects will be enrolled and randomized in a 1:1 ratio to receive a single dose (45 mg) of either CT-P43 or EU-approved Stelara to collect preliminary safety data for CT-P43. In Part 2, subjects will be enrolled and randomized in a 1:1:1 ratio to receive a single dose (45 mg) of CT-P43, EU-approved Stelara, or US-licensed Stelara to demonstrate PK similarity. Each part will proceed independently, and subjects will be randomized to either Part 1 or Part 2 of the study subsequently. All subjects in Part 1 and Part 2 will undergo the same assessments. In each treatment arm in Part 1 and Part 2, all subjects will receive a study drug subcutaneously via PFS. The randomization to treatment assignment will be stratified by study center and body weight as measured at baseline to balance subject weight across treatment groups. Subjects will be confined to the study center until all required 24-hour post-dose assessments have been completed and will be discharged on Day 2. Subsequent visits will be carried out on an out-patient basis up to EOS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 271
• Est. completion date: February 24, 2021
• Est. primary completion date: February 24, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy male subjects, between the ages of 18 and 55 years.

2. Subject with a BMI between 18.5 and 29.9 kg/m2. Weight between 60 to 100 kg.

3. Subject must agree to use medically acceptable methods of contraception consistent with local regulations during the course of the study and for 18 weeks after administration of the study drug.

4. Subject is informed and able to understand the full nature and purpose of the study, including possible risks and side effects, and is given ample time and opportunity to read and understand this information.

Exclusion Criteria:

1. Subject has a prohibited medical history and/or current condition.

2. Subject is planning to father a child or donate sperm within 18 weeks after the administration of the study drug (Day 1).

3. Subject previously received any biologic agents

4. In the opinion of the investigator, the subject is not eligible for the study participation for any reason.

5. Subject is vulnerable.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Biological:
• CT-P43
45mg single dose
• EU-approved Stelara
45mg single dose
• US-licensed Stelara
45mg single dose

Locations

Country	Name	City	State
New Zealand	Christchurch Clinical Studies Trust Limited	Christchurch	Canterbury
New Zealand	Auckland Clinical Studies Limited	Grafton	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Celltrion

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Demonstrate PK similarity	under the concentration-time curve from time zero to infinity (AUC0-inf) of CT-P43, EU-approved Stelara, and US-licensed Stelara	through study completion, up to day 127
Primary	Demonstrate PK similarity	maximum serum concentration (Cmax) of CT-P43, EU-approved Stelara, and US-licensed Stelara	through study completion, up to day 127